Encephalbol - instructions for use, reviews, analogs and formulations (100 mg tablets, suspension or syrup) of a drug to treat developmental delays in adults, children (including infants and newborns), and in pregnancy

In this article, you can read the instructions for using the drug Encephalbol. There are reviews of visitors to the site - consumers of this medication, as well as opinions of doctors specialists on the use of Encephalus in their practice. A big request is to actively add their feedback on the drug: the medicine helped or did not help get rid of the disease, which were observed complications and side effects, possibly not declared by the manufacturer in the annotation. Encephalbol analogues in the presence of existing structural analogues.Use to treat developmental delays and encephalopathy in adults, children (including infants and newborns), as well as during pregnancy and lactation.

Encephalbol - Nootropic preparation. Increases pathologically reduced metabolism in the brain tissue, which is due to increased capture and utilization of glucose, increases the metabolism of nucleic acids and the release of acetylcholine in the synapses of nerve cells, improves cholinergic transmission in nervous tissue.

Piritinol (the active substance of the Encephabol preparation) promotes the stabilization of the structure of the cell membranes of neurons and their function by inhibiting lysosomal enzymes, preventing the formation of free radicals.

Encephabol improves the rheological properties of blood, increases the plasticity of red blood cells by increasing the ATP content in their membrane, which leads to a decrease in blood viscosity and an improvement in blood flow.

It improves blood circulation in ischemic areas of the brain, increases their oxygenation, intensifies glucose metabolism in the primary ischemic areas of the brain. As a result, memory parameters are improved and disturbed metabolic processes in nervous tissue are restored,which contributes to the full functioning of its cells.

Composition

Pyrithinol dihydrochloride monohydrate + auxiliary substances.

Pharmacokinetics

After taking the drug inside Encephabol quickly absorbed from the digestive tract. Bioavailability averages 85% (76-93%). The binding with plasma proteins is 20-40%. Pyrithinol and its metabolites penetrate the blood-brain barrier (GEB), metabolites accumulate mainly in the gray matter of the brain. When you re-receive cumulation is not observed. Pyrithinol is rapidly biotransformed. Conjugated metabolites are excreted mainly by the kidneys. The total excretion in the urine within 24 hours is 72.4-74.2%, with most of the dose being excreted within the first 4 hours after administration. Through the intestine only 5% is excreted.

Indications

• symptomatic treatment of dementia syndrome (including primary degenerative dementia, vascular dementia and mixed forms), accompanied by memory impairment, thinking, ability to concentrate, fast fatigue, lack of motivation and motivation, affective disorders;
• primary degenerative dementia, vascular dementia and mixed forms;
• symptomatic therapy of chronic disorders of mental performance;
• post-traumatic encephalopathy;
• cerebral atherosclerosis;
• consequences of encephalitis;
• impaired mental function;
• cerebroasthenic syndrome in children;
• encephalopathy in children.

Forms of release

Tablets coated with 100 mg.

Suspension for oral administration (sometimes mistakenly referred to as syrup).

Instructions for use and effective doses

The dosage regimen is set individually, depending on the severity of the condition and the effectiveness of therapy.

For adults, the average dose is 600 mg per day (2 tablets or 10 ml of suspension 3 times a day).

Newborn Encephabol is prescribed from 3 days after birth to 20 mg (1 ml of suspension) per day for a month, the drug should be given in the morning. For children aged 2 months, the dose is increased by 20 mg (1 ml) every week until the daily dose reaches 100 mg (5 ml suspension).

Children aged 1 to 7 years are prescribed a daily dose of 50 mg to 300 mg, depending on the indications (2.5-5 ml suspension 1-3 times a day).

For children over 7 years of age, the daily dose ranges from 50 mg to 600 mg (2.5-10 ml suspension or 1-2 tablets 1-3 times a day).

Take the drug should be during or after a meal. In cases of sleep disorders, the last daily dose should not be taken in the evening or at night. It should be noted that in 1 teaspoonful - 5 ml of suspension.

The duration of treatment depends on the clinical picture of the disease. In acute conditions and the appointment of the drug in high doses, a noticeable therapeutic effect is achieved within a few hours or days.

In chronic diseases (including the consequences of craniocerebral trauma or with dementia), noticeable therapeutic success is achieved after 2-4 weeks of treatment. The optimal and stable effect usually occurs in 6-12 weeks. The duration of treatment for chronic diseases should be at least 8 weeks.

In newborns with a high risk of perinatal pathology, the median duration of treatment is 6 months, and after 3 months, the presence of indications for further treatment should be checked.

Side effect

• nausea, vomiting;
• diarrhea;
• loss of appetite;
• change in taste sensitivity;
• sleep disorders;
• increased excitability;
• headache;
• dizziness;
• fatigue;
• allergic reactions of varying severity, usually manifested in the form of rashes on the skin or mucous membranes;
• itching;
• fever.

Contraindications

Absolute contraindications

• hypersensitivity to pyrithinol.

Relative contraindications

• kidney disease in anamnesis;
• severe liver dysfunction;
• marked changes in the pattern of peripheral blood;
• acute autoimmune diseases (including systemic lupus erythematosus);
• myasthenia gravis;
• pemphigus.

Application in pregnancy and lactation

If it is necessary to use Encephalbol during pregnancy or during lactation (breastfeeding), the prospective benefit for the mother and the potential risk to the fetus or baby should be correlated.

Pyrithinol penetrates through the placental barrier, in small amounts is excreted in breast milk.

In experimental studies, the presence of a teratogenic or embryotoxic effect of pyrithinol has not been established.

Use in children

Do not recommend appointing the drug in the evening and at night to children with increased excitability.

Newborn Encephabol is prescribed from 3 days after birth to 20 mg (1 ml of suspension) per day for a month, the drug should be given in the morning. For children aged 2 months, the dose is increased by 20 mg (1 ml) every week until the daily dose reaches 100 mg (5 ml suspension).

Children aged 1 to 7 years are prescribed a daily dose of 50 mg to 300 mg, depending on the indications (2.5-5 ml suspension 1-3 times a day).

For children over 7 years of age, the daily dose ranges from 50 mg to 600 mg (2.5-10 ml suspension or 1-2 tablets 1-3 times a day).

special instructions

In patients with rheumatoid arthritis and other chronic joint diseases, there is an increased sensitivity to compounds that include the SH group, incl. to pyrithinol. These patients are at increased risk of developing hypersensitivity reactions, immunopathological reactions, as well as violations of taste sensitivity and liver function. When treating this category of patients, systematic monitoring of general blood, urine, liver function, immunological parameters is necessary.

Do not administer Encephabol suspension to patients with fructose intolerance, becausethe composition of the drug includes sorbol.

Reactions of hypersensitivity to the drug may occur in patients with hypersensitivity to D-penicillamine, as the latter has a similarity to pyrithinol in chemical structure (thiol groups).

Impact on the ability to drive vehicles and manage mechanisms

When using Encephalbol according to indications, as a rule, there are no restrictions for those activities that require increased attention, rapid psychomotor reactions. However, given the likelihood of individual differences in the response of individual patients to the drug, at the beginning of treatment and with increasing doses, the possibility of disturbing the rate of psychomotor reactions should be considered.

Drug Interactions

With the simultaneous use of Encephabol can potentiate the side effects of penicillamine, preparations of gold and sulfasalazine.

Clinically significant interaction of Encephalbol with other drugs has not been established.

Analogues of Encephabol

Structural analogs for the active substance:

• Pyriditol;
• Energol.

Analogues for the pharmacological group (nootropics):

• Amylonosar;
• Aminalon;
• Ampasse;
• Vinpotropil;
• Gamalon;
• Ginkyo;
• Ginos;
• Glaser;
• Gliatilin;
• Glycine;
• Gopantam;
• Delecite;
• Demanol;
• Idebenon;
• Intelland;
• Calcium gopentate;
• Combbitropyl;
• Cortexin;
• Cortexin for children;
• Coenzyme Q10 with Ginkgo;
• Lucetsam;
• Meclofenoxate hydrochloride;
• Mexipridol;
• Mexiprim;
• Mexicin;
• Memotropized;
• Minisem;
• Neuromet;
• Nootropil;
• Noochlin Rompharm;
• Noocetam;
• Omaron;
• Pantogam is an asset;
• Pantogam;
• Pantokaltsin;
• Pikamilon;
• Piraben;
• Pyramids;
• Pyramidal;
• Piracesine;
• Piracetam;
• Pyriditol;
• Pramistar;
• Semax;
• Stamine;
• Tenoten;
• Tenoten for children;
• Thiocetam;
• Fezam;
• Fenibut;
• Phenotropil;
• Holilitil;
• Cebrilysin;
• Ceraxon;
• Cerebramine;
• Cerebrial;
• Cerebrosolate;
• Cerebrolysin;
• Cerepro;
• Cereton;
• The escotrope.

Similar medicines:

Other medicines: